Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-b activity in mouse atheromata in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1360-1365

  Shon, Soo Min ^a   Choi, Yongdoo ^b   Kim, Jeong Yeon ^a   Lee, Dong Kun ^c   Park, Jin Yong ^a   Schellingerhout, Dawid ^d   Kim, Dong Eog ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Songdo Global University Campus   (South Korea)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Atherosclerosis; Cathepsin B; Molecular imaging; Photodynamic therapy; Photosensitizer; Protease mediated theranostic agent

Indexed keywords

APOLIPOPROTEIN E; CATHEPSIN B; DNA NUCLEOTIDYLEXOTRANSFERASE; L SR15; PHOTOSENSITIZING AGENT; PROTEINASE; SODIUM CHLORIDE; TALAPORFIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CONTINUOUS WAVE LASER; DIODE LASER; ENZYME ACTIVITY; IN VIVO STUDY; MOLECULAR IMAGING; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION;

ATHEROSCLEROSIS; CATHEPSIN-B; MOLECULAR IMAGING; PHOTODYNAMIC THERAPY; PHOTOSENSITIZER; PROTEASE-MEDIATED THERANOSTIC AGENT;

ANIMALS; APOLIPOPROTEINS E; CAROTID ARTERIES; CATHEPSIN B; DISEASE MODELS, ANIMAL; DRUG ERUPTIONS; ERYTHEMA; INJECTIONS, INTRAVENOUS; MICE; MICE, KNOCKOUT; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PLAQUE, ATHEROSCLEROTIC; PORPHYRINS; RANDOM ALLOCATION; REFERENCE VALUES;

EID: 84879126791     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301290     Document Type: Article

References (20)

1. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114:55-62.
2. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, Shi GP, Libby P, Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-Activatable fluorescence sensor. Circulation. 2007;115:2292-2298.
3. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
4. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41:15S-22S.
5. Kim DE, Kim JY, Schellingerhout D, Shon SM, Jeong SW, Kim EJ, Kim WK. Molecular imaging of cathepsin B proteolytic enzyme activity reflects the inflammatory component of atherosclerotic pathology and can quantitatively demonstrate the antiatherosclerotic therapeutic effects of atorvastatin and glucosamine. Mol Imaging. 2009;8:291-301.
6. Kim DE, Kim JY, Schellingerhout D, Kim EJ, Kim HK, Lee S, Kim K, Kwon IC, Shon SM, Jeong SW, Im SH, Lee DK, Lee MM, Kim GE. Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vasc Biol. 2010;30:449-456.
7. Shon SM, Park JH, Nahrendorf M, Schellingerhout D, Kim JY, Kang BT, Jeong SW, Kim EJ, Ryu JH, Kim K, Kwon IC, Lee DK, Lee MM, Kim DE. Exercise attenuates matrix metalloproteinase activity in preexisting atherosclerotic plaque. Atherosclerosis. 2011;216:67-73.
8. Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol. 2001;21:759-764.
9. Muller JE. New light on an old problem photodynamic therapy for atherosclerosis. J Am Coll Cardiol. 2008;52:1033-1034.
10. Sharman WM, Allen CM, van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today. 1999;4:507-517.
11. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A light-Activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010;6:2041-2049.
12. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res. 2006;66:7225-7229.
13. Lee DK, Choi Y, Shon SM, Schellingerhout D, Park JE, Kim DE. Atorvastatin and clopidogrel interfere with photosensitization in vitro. Photochem Photobiol Sci. 2011;10:1587-1592.
14. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968;13:222-257.
15. Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, McCarthy JR, Ntziachristos V, Bouma BE, Jaffer FA, Tearney GJ. Intraarterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17:1680-1684.
16. Waksman R, McEwan PE, Moore TI, Pakala R, Kolodgie FD, Hellinga DG, Seabron RC, Rychnovsky SJ, Vasek J, Scott RW, Virmani R. PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J Am Coll Cardiol. 2008;52:1024-1032.
17. Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, Hoang B, Ringenberg MA, Qin P, Goodman KB, Willette RN, Macphee CH, Jucker BM, Sehon CA, Gough PJ. Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/-mouse: magnetic resonance imaging assessment. Arterioscler Thromb Vasc Biol. 2010;30:253-259.
18. Gaudio E, Carpino G, Grassi M, Musca A. [Morphological aspects of atherosclerosis lesion: past and present]. Clin Ter. 2006;157:135-142.
19. Lee SJ, Park K, Oh YK, Kwon SH, Her S, Kim IS, Choi K, Lee SJ, Kim H, Lee SG, Kim K, Kwon IC. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials. 2009;30:2929-2939.
20. Lee DK, Nahrendorf M, Schellingerhout D, Kim DE. Will molecular optical imaging have clinically important roles in stroke management, and how? J Clin Neurol. 2010;6:10-18.